Tozadenant (SYN-115) is an adenosine A2A receptor antagonist. Treatment of Parkinson¡¯s disease, dopaminergic neurotransmission disorders.

June 21, 2017

prudect name : Tozadenant (SYN-115) is an adenosine A2A receptor antagonist. Treatment of Parkinson¡¯s disease, dopaminergic neurotransmission disorders.Tozadenant;SYN-115 Synonyms: CAS NO: 870070-55-6Molecular Formula: C19H26N4O4SMolecular Weight: 406.50Purity: 98$ minSolubility: In DMSOStorage:…

📌

0💬 read more

TAK-875 is a potent, selective and orally bioavailable GPR40 agonist with EC50 of 0.072 ¦ÌM. In treatment of diabetes.

prudect name : TAK-875 is a potent, selective and orally bioavailable GPR40 agonist with EC50 of 0.072 ¦ÌM. In treatment of diabetes.TAK-875 Synonyms: CAS NO: 1000413-72-8Molecular Formula: C29H32O7SMolecular Weight: 524.64Purity:…

📌

0💬 read more

TGR5 Receptor Agonist, a potent TGR5(GPCR19) agonist, showed improved potency in the U2-OS cell assay (pEC50 = 6.8) and in melanophore cells (pEC50 = 7.5).

prudect name : TGR5 Receptor Agonist, a potent TGR5(GPCR19) agonist, showed improved potency in the U2-OS cell assay (pEC50 = 6.8) and in melanophore cells (pEC50 = 7.5).TGR5 Synonyms: CAS…

📌

0💬 read more

prudect name : Topotecan hydrochlorideSynonyms: CAS NO: 119413-54-6Molecular Formula: C23H23N3O5.HCl;C23H24ClN3O5Molecular Weight: 457.91Purity: 99%Solubility: In DMSOStorage:

prudect name : Topotecan hydrochloride Synonyms: CAS NO: 119413-54-6Molecular Formula: C23H23N3O5.HCl;C23H24ClN3O5Molecular Weight: 457.91Purity: 99%Solubility: In DMSOStorage: −20°C 2 years web site: www.medchemexpress.com

📌

0💬 read more

prudect name : Thiosalicylic acidSynonyms: CAS NO: 147-93-3Molecular Formula: C7H6O2SMolecular Weight: 154.18Purity: 98%Solubility: Storage: −20°C

prudect name : Thiosalicylic acid Synonyms: CAS NO: 147-93-3Molecular Formula: C7H6O2SMolecular Weight: 154.18Purity: 98%Solubility: Storage: −20°C 2 years web site: www.medchemexpress.com

📌

0💬 read more

TPT-260 2Hcl (TPU260 2Hcl) is a thiophene thiourea derivative with molecule weight 260.00 in free base form; There is no formal name yet, we temporally call this molecule as TPT-260.

prudect name : TPT-260 2Hcl (TPU260 2Hcl) is a thiophene thiourea derivative with molecule weight 260.00 in free base form; There is no formal name yet, we temporally call this…

📌

0💬 read more

prudect name : TolvaptanSynonyms: CAS NO: 150683-30-0Molecular Formula: C26H25ClN2O3Molecular Weight: 448.94Purity: 99%Solubility: In DMSOStorage: −20°C

prudect name : Tolvaptan Synonyms: CAS NO: 150683-30-0Molecular Formula: C26H25ClN2O3Molecular Weight: 448.94Purity: 99%Solubility: In DMSOStorage: −20°C 2 years web site: www.medchemexpress.com

📌

0💬 read more

Tirasemtiv(CK 2017357) is a a small-molecule fast-skeletal-troponin activator, which is being developed as a potential treatment for diseases and conditions associated with aging, muscle weakness and wasting or neuromuscular dysfunction.

prudect name : Tirasemtiv(CK 2017357) is a a small-molecule fast-skeletal-troponin activator, which is being developed as a potential treatment for diseases and conditions associated with aging, muscle weakness and wasting…

📌

0💬 read more

Ticagrelor(274693-27-5) (trade name Brilinta in the US, Brilique and Possia in the EU) is a platelet aggregation inhibitor produced by AstraZeneca. The drug was approved for use in the European Union by the European Commission on December 3, 2010. The drug was approved by the US Food and Drug Administration on July 20, 2011.

prudect name : Ticagrelor(274693-27-5) (trade name Brilinta in the US, Brilique and Possia in the EU) is a platelet aggregation inhibitor produced by AstraZeneca. The drug was approved for use…

📌

0💬 read more

ARQ-197 has been shown to prevent HGF/c-met induced cellular responses in vitro. ARQ-197 possesses antitumor activity; inhibiting proliferation of A549, DBTRG and NCI-H441 cells with IC50 of 0.38, 0.45, 0.29 ¦ÌM. Treatment with ARQ-197 results in a decrease in phosphorylation of the MAPK signaling cascade and prevention of invasion and migration. In addition, ectopic expression of c-Met in NCI-H661, a cell line having no endogenous expression of c-Met, causes it to acquire an invasive phenotype that is also suppressed by ARQ-197. Although the addition of increasing concentrations of ARQ-197 does not significantly affect the Km of ATP, exposure of c-Met to 0.5 ¦ÌM ARQ-197 decreased the Vmax of c-Met by approximately 3-fold. The ability of ARQ-197 to decrease the Vmax without affecting the Km of ATP confirmed that ARQ-197 inhibits c-Met through a non¨CATP-competitive mechanism and may therefore account for its high degree of kinase selectivity. ARQ-197 prevents human recombinant c-Met with a calculated inhibitory constant Ki of approximately 355 nM. Although the highest concentration of ATP used is 200 ¦ÌM, the potency of ARQ-197 against c-Met is not reduced by using concentrations of ATP up to 1 mM. ARQ-197 blocks c-Met phosphorylation and downstream c-Met signaling pathways. ARQ-197 suppresses constitutive and ligand-mediated c-Met autophosphorylation and, by extension, c-Met activity, in turn leading to the inhibition of downstream c-Met effectors. ARQ-197 induction of caspase-dependent apoptosis is increased in c-Met¨Cexpressing human cancer cells including HT29, MKN-45, and MDA-MB-231 cells

prudect name : ARQ-197 has been shown to prevent HGF/c-met induced cellular responses in vitro. ARQ-197 possesses antitumor activity; inhibiting proliferation of A549, DBTRG and NCI-H441 cells with IC50 of…

📌

0💬 read more

Archive for June 2017